Market statusData NSENot investment advice
BLISSGVS

BLISSGVS Latest Share Price (BLISSGVS)

NSE: BLISSGVSBSE 506197HealthcarePharmaceuticalswww.blissgvs.com
TechnicalsTV Chart
527.10
3.55+0.68%
Overall Score73/100
Day range524
₹527.10
533
52-week118
₹527.10
553
Above low+346.7%
Below high4.7%
Range position94%
Open523.55
Prev Close523.55
Bid527.07157
Ask527.13100

TODAY IN ONE LINE

With a market cap of ₹7,678.47 Cr., it trades at a P/E of 56.25. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume393.3K66%vs 20D avg
Price Band
Lower Band0
Upper Band0
Tick Size0.00
Daily Volatility0.00%
Annualised Vol0.00%
Market Cap₹7,678.47 Cr.
Promoter35.36%
Face Value₹1
Fwd P/E
PEG2.04
EV/EBITDA11.17
P/S6.03
ROA
Beta1.19
Div Payout8.34%
THE STOCK SCORE
Overall Score73/100
Updated 03 Jul

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

BLISSGVS flags & news 

Key strengths, potential risks, and recent updates.

5 green flags🚩 2 red flags

Green Flags

  • Earnings GrowthEPS (TTM) grew by a solid 124.7% YoY
  • Quarterly OutperformanceLatest quarter Sales up 28.9% and Profit up 33.0%
  • Healthy Operating MarginsOPM is structurally strong at 21.7%
  • Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • Zero Pledge RiskNo recent active promoter pledging found

Red Flags

Latest BLISSGVS News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

No recent changes found for this period.
🔒Prime: full history + alerts on this stock
Valuation

BLISSGVS valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for BLISSGVS, framed against the sector median so the premium or discount is obvious at a glance.

BLISSGVS trades at a P/E of 56.25× and P/B of 6.42×.

Key MetricsMarket + reported · 02 Jul 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹7,678.47 Cr.
P/E Ratio
56.25
P/B Ratio
6.42
EPS
₹4.72
Profitability

Profitability

ROE
10.94%
ROCE
11.94%
Net Margin
13.93%
Op Margin
21.74%
Growth

Growth

EPS YoY
124.7%
Revenue YoY
29.8%
Qtr Sales
28.88%
Qtr Profit
33.03%
Financial Health

Financial Health

Debt / Equity
Book Value
₹116.14
Div Yield
0.21%
Promoter Holding
35.36%
Technicals

BLISSGVS technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BLISSGVS — derived from the latest tape, not yesterday's close.

BLISSGVS last traded at ₹527.1 with an intraday range of ₹523.55–₹532.8 — latest indicator, pivot and CPR signals below.

Last updated: 14 September 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹527.10
LevelPrice (₹)Distance% Δ
R4550.58+23.48+4.46%
R3541.33+14.23+2.70%
R2537.07+9.97+1.89%
R1532.08+4.98+0.95%
PIVOT527.820.720.14%
CURRENT527.10
S1522.83-4.27-0.81%
S2518.57-8.53-1.62%
S3513.58-13.52-2.56%
S4504.33-22.77-4.32%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 527.46P: 527.82TC: 528.17
R1
R2
R3
R4
indicator
LTP: 527.10
PDH: 547.40
PDL: 514.15
● Market Sentiment

BLISSGVS is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Narrower, suggesting likely for trending moves

● Opening Range

Day's range:

● Price Position

Trading Inside opening range

Financials

BLISSGVS financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for BLISSGVS — consolidated or standalone — with margins, YoY growth and key ratios inline.

BLISSGVS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹7,678.47 Cr. and reported EPS of ₹4.72.

iTap any row for a plain-English meaningChange vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2025Mar 2026
Revenue from Operations810
927
14.5%
Sales Growth YoY %Derived5.13%
14.50%
Other Income36
74
101.5%
Total Income846
1,001
18.2%
414
425
2.7%
Gross ProfitDerived396
502
26.8%
Gross Margin %Derived48.91%
54.15%
269
338
25.5%
EBITDA (Operating Profit)Derived127
164
29.5%
OPM %Derived15.65%
17.69%
38
43
14.6%
Profit Before Tax (PBT)126
190
50.9%
35
55
55.0%
Effective Tax %Derived28.16%
28.94%
Total Profit for Period90
135
49.3%
Less: Non-controlling Interests6
6
6.0%
Net Profit (Owner's PAT)Derived84
129
53.2%
Net Profit Margin %Derived10.41%
13.93%
PAT Growth YoY %Derived11.72%
53.18%
Earnings Per Share (EPS ₹)8.00
12.21
52.6%
Diluted Shares Outstanding (Cr)11
11
0.4%
Other Comprehensive Income (Net of Tax)-2
2
186.6%
Total Expenses (incl. D&A & Interest)721
811
12.6%
Material Cost % of RevenueDerived46.00%
41.66%
Employee Cost % of RevenueDerived13.84%
14.72%
Other Cost % of RevenueDerived19.43%
21.74%
Interest Coverage (x)Derived11.98x
10.87x
Sales CAGR · 3Y
+7.2%
Sales CAGR · 5Y
+9.9%
PAT CAGR · 3Y
+22.1%
PAT CAGR · 5Y
+13.6%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

BLISSGVS segment analysis : revenue and profit mix.

Disclosed business segments at BLISSGVS with their share of revenue and profit, switchable between consolidated and standalone reporting.

BLISSGVS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for BLISSGVS.

Our AI distills the core fundamental drivers supporting BLISSGVS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

BLISSGVS's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.

bull case

What you're getting.

  • Latest quarterly EPS grew 128.9% YoY, demonstrating explosive earnings momentum.

  • TTM EPS grew 124.7% YoY, sustaining strong profit acceleration despite market headwinds.

  • Operating margin 14.08% reflects solid operational efficiency in competitive pharma sector.

  • Net profit margin 13.9% indicates strong pricing power and cost management capabilities.

  • Debt-to-equity ratio 0.0177 shows exceptionally low leverage and robust financial flexibility.

bear case

Key Risks.

  • FII holdings declined from 17.17% to 12.65%, signaling reduced foreign investor confidence.

  • Dividend yield 0.19% offers minimal income return for equity shareholders.

  • ROE 8.36% lags peer benchmarks, indicating suboptimal capital efficiency.

  • ROCE 11.70% below industry leaders, suggesting weaker returns on invested capital.

  • Net debt negative at ₹1,933 Cr indicates persistent cash burn despite operating profits.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 73 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Return-quality risk. ROE below 8% would indicate weaker capital compounding.

  • Income thesis breaks if the dividend is cut or yield falls below 0.10%.

Shareholding

BLISSGVS shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in BLISSGVS — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

AnnualJun 2026

Promoters35.01%0.35%
Public47.45%1.70%
FII8.07%2.38%
DII9.47%4.43%

Ownership Distribution

Promoters
35.01%
Retail & Public
47.45%
Foreign Institutions
8.07%
Domestic Institutions
9.47%

Category Trends

Foreign Institutions Breakdown
Total Holding: 8.07%
Net Change: -2.38%
Category Total8.07%
Total Holding8.07%
Net Change-2.38%
Not Fully Disclosed

⚠️Partial Disclosure Notice

Individual institutions below total 4.19%, but category aggregate is 8.07%. Some institutions may not be disclosed by the company as per regulatory requirements.

Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
Coeus Global Opportunities Fund
1.75%
0.01%
-0.01%
Jun 2026
Arian Investment Limited
1.36%
1.09%
-1.09%
Jun 2026
MATEUS LTD
1.08%
1.08%
+1.08%
Jun 2026
ARK GLOBAL EMERGING COMPANIES LP
0.00%
1.42%
-1.42%
Jun 2026
Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund
0.00%
0.00%
0.00%
Jun 2026
ASPIRE EMERGING FUND
0.00%
0.00%
0.00%
Jun 2026
Polus Global Fund
0.00%
0.00%
0.00%
Jun 2026
QUADRATURE TRADING VCC - SUB-FUND NO. 1
0.00%
1.23%
-1.23%
Jun 2026
Peers

BLISSGVS peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BLISSGVS is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
SUN PHARMACEUTICAL IND L
₹4.42 Lakh Cr
Best Profit Growth
ALBERT DAVID
2240.75 %
Highest Dividend Yield
SANOFI INDIA
3.99 %

Peer Comparison

Company Name
09 · Chart Patterns

BLISSGVS chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for BLISSGVS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

BLISSGVS delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for BLISSGVS over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in BLISSGVS stood at 53.7% of traded volume, against a 20-day average of 44.4%.

Avg Delivery (20D)44.4%+9.3 ppt latest vs avg
Highest Delivery57.7%on 24 Jun
Avg Volume (20D)11.50 L20-day run-rate
Conviction Trend↓ Weakening+9.3 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

BLISSGVS announcements: results, concalls, ratings, M&A.

Filings BLISSGVS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

BLISSGVS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 110 documents below.

  1. 04 Sept 2026ESOP/ESOS/ESPSView PDF

    ESOP/ESOS/ESPS

    Bliss GVS Pharma Limited has informed the Exchange regarding the ESOP Allotment Committee of the Company at its meeting held today i.e. September…

  2. 02 Sept 2026UpdatesView PDF

    Updates

    SBI Capital Markets Ltd has submitted to the Exchange a copy of Post offer advertisement in accordance with Regulation 18(12) of the SEBI (SAST)…

  3. 25 Aug 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Extension of Special Window for Re-Lodgement of…

  4. 21 Aug 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the Advertisement of the Postal Ballot Notice.

  5. 20 Aug 2026Shareholders meetingView PDF

    Shareholders meeting

    Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot

Corporate Actions

BLISSGVS dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue BLISSGVS has declared, sequenced by announce and record date.

BLISSGVS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

Insider Activity

BLISSGVS insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in BLISSGVS as reported to SEBI — buying and selling signals from the people who know the business best.

BLISSGVS insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
Mr. Gagan Harsh SharmaInsider10 Jun 2025buy+2.0 K₹2.69 L₹136.73
Mr. Gagan Harsh SharmaInsider09 Jun 2025buy+46.7 K₹63.78 L₹136.70
Mr. Gagan Harsh SharmaInsider22 May 2025buy+4.7 K₹5.72 L₹121.48
Mr. Gagan Harsh SharmaInsider21 May 2025buy+37.3 K₹45.16 L₹121.20
Mr. Gagan Harsh SharmaInsider20 May 2025buy+41.6 K₹50.54 L₹121.47
Mrs. Vibha Gagan SharmaInsider21 Mar 2025buy+25.0 K₹30.66 L₹122.63
Mrs. Vibha Gagan SharmaInsider20 Mar 2025buy+75.0 K₹90.47 L₹120.63
Mr. Narsimha Shibroor KamathInsider19 Feb 2025buy+23.0 K₹30.73 L₹133.59
Mr. Narsimha Shibroor KamathInsider18 Feb 2025buy+77.0 K₹98.19 L₹127.52
About the Company

About BLISSGVS: business, sector, key facts.

What BLISSGVS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

BLISSGVS operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BLISSGVS, BSE: 506197.

BLISSGVS
Healthcare

BLISSGVS

NSE · BLISSGVS·BSE · 506197·www.blissgvs.com

Bliss GVS Pharma Limited is a pharmaceutical company headquartered in Mumbai, India, established in 1984. Their core business centers around the development, manufacture, and marketing of a diverse range of pharmaceutical formulations both domestically within India and internationally through exports.

The company's product portfolio is extensive and encompasses a wide spectrum of dosage forms. This includes capsules, tablets (including effervescent), injections, suspensions, liquids, creams, ointments, gels, eye and ear drops, suppositories, pessaries, transdermal patches, and other topical preparations like lotions, balms, and sprays. They also produce various other healthcare products such as soaps, shampoos, nasal inhalers, and personal care items.

Bliss GVS's therapeutic areas covered are equally broad, reflecting their commitment to providing a comprehensive range of medications. Their offerings include products addressing pain relief (analgesics), digestive issues (antacids, anti-diarrheals, anti-emetics), infections (antibacterials, antifungals, anti-infectives), respiratory ailments (cough syrups, nasal decongestants), cardiovascular conditions, and many other therapeutic categories. This spans anti-diabetic, anti-inflammatory, anti-malarial, anti-helminthic and numerous other therapeutic areas, along with products for specific conditions such as erectile dysfunction, laryngitis, and pharyngitis. Furthermore, they offer health supplements, vitamins, and other over-the-counter (OTC) products.

In addition to their core pharmaceutical offerings, Bliss GVS expands into related health and personal care areas. They provide products like health and nutritional supplements, vitamin supplements, amino acid preparations, iron tonics, insect repellants, moisturizers, and vaginal hygiene products. This diversification demonstrates a strategy to cater to a wider consumer base beyond prescription medications.

company facts
Employees966
SectorHealthcare
HeadquartersMumbai, India
Market Cap₹7,678.47 Cr.
Listed OnNSE
leadership15 on record
Dr. Nandkumar Chodankar
Additional Non-Executive Independent Director
Mr. Deepak B. Sawant
Chief Financial Officer
Mr. Deepak Sawant
Chief Financial Officer
Mr. Gagan Sharma
Managing Director, Executive Director
Mr. Narsimha Kamath
Chief Executive Officer
Mr. Prashant Churi
Vice President of Technical Operations
Mr. Santosh Parab
Independent Director
Mr. Shibroor Narsimha Kamath
MD, CEO & Director
Mr. Shreekrushna Joshi
Head of Legal
Mr. Sourya Das
Associate Vice President
Ms. Aditi Bhatt
Compliance Officer, Company Secretary
Ms. Aditi Himanshu Bhatt
Compliance Officer, Company Secretary & Nodal Officer
§ ∞ · Plainly Answered

Questions investors ask about BLISSGVS (BLISSGVS).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of BLISSGVS (BLISSGVS)?

The current share price of BLISSGVS (BLISSGVS) is ₹527.10. Today, the stock has gained by ₹3.55 (0.68%), trading in a range of ₹523.55 to ₹532.80. The stock opened at ₹523.55 with a trading volume of 3,93,278 shares.

02Is BLISSGVS stock a good investment for long-term?

BLISSGVS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹7,678.47 Cr., P/E ratio of 56.25, ROE of 10.94%, and ROCE of 11.94%. The dividend yield stands at 0.21%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of BLISSGVS stock?

The 52-week high price of BLISSGVS (BLISSGVS) is ₹553.00, while the 52-week low is ₹118.00. Currently trading at ₹527.10, the stock is 346.69% above its 52-week low and 4.68% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy BLISSGVS stock at the current price?

Whether to buy BLISSGVS stock at ₹527.10 depends on multiple factors. The stock is currently trading with a P/E ratio of 56.25 and P/B ratio of 6.42. Today's performance shows a gain of 0.68%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of BLISSGVS and when is the next dividend?

BLISSGVS offers a dividend yield of 0.21%, which means for every ₹100 invested at the current price of ₹527.10, you can expect to receive approximately ₹0.21 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of BLISSGVS?

BLISSGVS's key financial metrics include: P/E Ratio: 56.25, P/B Ratio: 6.42, ROE: 10.94%, ROCE: 11.94%, Dividend Yield: 0.21%, EPS: ₹4.72, Book Value: ₹116.14, and Debt-to-Equity: 0. The company's market cap stands at ₹7,678.47 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is BLISSGVS stock performing today in the market?

BLISSGVS stock opened at ₹523.55 and is currently trading at ₹527.10, showing a gain of ₹3.55 (0.68%). The intraday high is ₹532.80 and low is ₹523.55. The trading volume stands at 3,93,278 shares, indicating moderate market participation today.

08What is the P/E ratio of BLISSGVS and what does it indicate?

BLISSGVS has a Price-to-Earnings (P/E) ratio of 56.25, which means investors are willing to pay 56.25 for every ₹1 of earnings. With an EPS of ₹4.72, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about BLISSGVS (BLISSGVS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.